WO2024254515A3 - Systems and methods to direct cellular therapies in vivo to an organ - Google Patents

Systems and methods to direct cellular therapies in vivo to an organ Download PDF

Info

Publication number
WO2024254515A3
WO2024254515A3 PCT/US2024/033096 US2024033096W WO2024254515A3 WO 2024254515 A3 WO2024254515 A3 WO 2024254515A3 US 2024033096 W US2024033096 W US 2024033096W WO 2024254515 A3 WO2024254515 A3 WO 2024254515A3
Authority
WO
WIPO (PCT)
Prior art keywords
systems
methods
vivo
cellular therapies
organ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/033096
Other languages
French (fr)
Other versions
WO2024254515A2 (en
Inventor
Robert EIL
Alexandra BARTLETT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health and Science University
Original Assignee
Oregon Health and Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health and Science University filed Critical Oregon Health and Science University
Priority to EP24820172.5A priority Critical patent/EP4724076A2/en
Publication of WO2024254515A2 publication Critical patent/WO2024254515A2/en
Publication of WO2024254515A3 publication Critical patent/WO2024254515A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/53—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Systems and methods to direct cellular therapies in vivo are provided. Systems and methods described herein include cells genetically modified to achieve at least two of: expression of a recombinant receptor, modulated expression of a trafficking signal, or modulated expression of a retention signal. The genetic constructs can be used to facilitate localized action of cellular therapies.
PCT/US2024/033096 2023-06-07 2024-06-07 Systems and methods to direct cellular therapies in vivo to an organ Ceased WO2024254515A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP24820172.5A EP4724076A2 (en) 2023-06-07 2024-06-07 Systems and methods to direct cellular therapies in vivo to an organ

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363506634P 2023-06-07 2023-06-07
US63/506,634 2023-06-07

Publications (2)

Publication Number Publication Date
WO2024254515A2 WO2024254515A2 (en) 2024-12-12
WO2024254515A3 true WO2024254515A3 (en) 2025-05-01

Family

ID=93796422

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/033096 Ceased WO2024254515A2 (en) 2023-06-07 2024-06-07 Systems and methods to direct cellular therapies in vivo to an organ

Country Status (2)

Country Link
EP (1) EP4724076A2 (en)
WO (1) WO2024254515A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210213063A1 (en) * 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
WO2022225981A2 (en) * 2021-04-19 2022-10-27 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210213063A1 (en) * 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
WO2022225981A2 (en) * 2021-04-19 2022-10-27 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies

Also Published As

Publication number Publication date
WO2024254515A2 (en) 2024-12-12
EP4724076A2 (en) 2026-04-15

Similar Documents

Publication Publication Date Title
Christians et al. Heat shock factor 1 and heat shock proteins: critical partners in protection against acute cell injury
NO20050504L (en) Recombinant tissue-protective cytokines and nucleic acids encoding such, for the protection, reconstruction and enhancement of responsive cells, tissues and organs
NO20032912D0 (en) Protection, reconstruction and strengthening of erythropoietin responsive cells, tissues and organs
AU5756298A (en) Attenuated salmonella strain used as a vehicle for oral immunization
DK1171573T3 (en) ARPE-19, as a platform cell line for encapsulated cell-based administration
CY1107179T1 (en) GENETICALLY MODIFIED PLANT CELLS AND PLANTS WITH INCREASED ENERGY PROTEIN STRUCTURE AND BRANCH ENZYME
IL148060A0 (en) Compositions and methods for improved cell culture
WO2023019225A3 (en) Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
DK1702979T3 (en) Improved keratinocyte culture and uses thereof
US20060008892A1 (en) Methods of and pharmaceutical compositions for improving implantation of embryos
WO2003078576A3 (en) Vector for transfection of eukaryotic cells
WO2024254515A3 (en) Systems and methods to direct cellular therapies in vivo to an organ
WO2024097311A3 (en) Hypoimmunogenic mail cells, methods of making and methods of using same
WO2023049918A3 (en) Cells expressing antigen- & sequence-specific t-cell receptors (tcrs) and methods of making the same using enforced tcr gene rearrangement
WO2023159136A3 (en) Epitope engineering of cell-surface receptors
WO2023141106A3 (en) Recombinant cell line expressing membrane proteins and vesicles prepared therefrom
WO2021141977A8 (en) Improved human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy
WO2023230534A3 (en) Use of fusion constructs for il-2 independent t cell therapy
WO2001011018A3 (en) Avian blastodermal cell lines
Henn et al. Full-time physioxic culture conditions promote MSC proliferation more than hypoxic preconditioning
ES2132027A1 (en) Development of an artificial skin by means of keratinocyte culture on a base of fibrin and human fibroblasts, and method for preparing this skin for transplantation
NO20021634D0 (en) Preparation of recombinant adenoviruses and adenovirus banks
WO1995006744A3 (en) Methods of suppressing immune response by gene therapy
Song et al. The high-level expression analysis of rhPA in the rhPA/gGH double-transgenic rabbits and its thrombolysis activity in vitro
D'Accardio Targeting the extracellular matrix to improve CAR-T cell therapy against Prostate Cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24820172

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2024820172

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024820172

Country of ref document: EP

Effective date: 20260107

ENP Entry into the national phase

Ref document number: 2024820172

Country of ref document: EP

Effective date: 20260107

ENP Entry into the national phase

Ref document number: 2024820172

Country of ref document: EP

Effective date: 20260107

ENP Entry into the national phase

Ref document number: 2024820172

Country of ref document: EP

Effective date: 20260107

WWP Wipo information: published in national office

Ref document number: 2024820172

Country of ref document: EP